Clover Health Investments Corp. · Q4 2021 earnings

Briefing

Reported financial results for the fourth quarter and full year of 2021.

Clover Health's Q4 2021 total revenue was $432.0 million, a 160% increase year-over-year. The company is expecting significant growth in revenue and lives under management while at the same time believes it is driving operating efficiencies and improved MCRs.

• Total revenue was $432.0 million, up 160% year-over-year.
• Lives under Clover Assistant Management increased 223% year-over-year.
• The company expects 2022 total revenue to exceed $3 billion, driven by projected 90% year-over-year growth in lives under management.
• Clover expects 2022 operating expenses as a percentage of revenue and the Medical Care Ratio (MCR) for its Medicare Advantage (MA) plans to decrease meaningfully from 2021.

Headline financials

Revenue & EPS history

For full-year 2022, Clover Health is providing the following guidance and commentary:Total revenues are expected to be in the range of $3.0 billion to $3.4 billion. This includes projected MA revenue of $1.0 billion to $1.1 billion and Direct Contracting revenue of $2.0 billion to $2.3 billion. Medicare Advantage membership is expected to average 84,000 - 85,000, a growth rate of 26% - 27% as compared to the 2021 average. For the Direct Contracting program, the Company expects the average number of aligned beneficiaries to be 160,000 - 165,000, compared to an average of 62,125 in 2021 and our prior guidance of 125,000. GAAP MA MCR is expected to be in the range of 95% - 99%. This improvement versus 2021 is driven by a combination of expected operational efficiencies, increased risk scores and slightly lower COVID-19 costs. Direct Contracting Margin is also expected to improve versus 2021 levels. Any significant developments related to COVID-19 and/or historical utilization trends could impact these expectations. Adjusted Operating Expenses (Non-GAAP) (1) are expected to be between $330 million and $345 million. Adjusted Operating Expenses as a percentage of revenue (Non-GAAP)(1) is expected to be 10% - 12% compared to 18% in 2021.